open access

Vol 52, No 3 (2018)
Original research articles
Submitted: 2017-02-24
Get Citation

Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity

Ewa Sobieszczuk, Justyna Kubiszewska, Marta Lipowska, Piotr Szczudlik, Beata Szyluk, Małgorzata Dutkiewicz, Anna Kostera-Pruszczyk
DOI: 10.1016/j.pjnns.2017.12.011
·
Neurol Neurochir Pol 2018;52(3):364-367.

open access

Vol 52, No 3 (2018)
Original research articles
Submitted: 2017-02-24

Abstract

Aim

To assess interleukin 15 (IL-15) serum levels in patients with seropositive myasthenia gravis (MG); searching for potential relationship between IL-15 levels and clinical features such as gender, age at onset, clinical presentation or treatment received.

Background

IL-15 plays pivotal role in T-cell dependent autoimmunity. Increased IL-15 serum levels have been reported in several autoimmune diseases including MG patients from Japan.

Patients and methods

Sera of 42 seropositive MG patients (66.7% women), mean age 50.6±23.7 years) have been tested by ELISA for IL-15 levels.

Results

There were no statistically significant differences between IL-15 serum levels in MG patients in comparison with controls as well as between subgroups of MG patients (early vs. late onset and thymoma MG). Mean/median IL-15 serum levels were similar in MG patients treated with corticosteroids (CS) and CS naïve. Outliers (very high values) were seen only in untreated generalized MG patients.

Conclusions

Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity.

Abstract

Aim

To assess interleukin 15 (IL-15) serum levels in patients with seropositive myasthenia gravis (MG); searching for potential relationship between IL-15 levels and clinical features such as gender, age at onset, clinical presentation or treatment received.

Background

IL-15 plays pivotal role in T-cell dependent autoimmunity. Increased IL-15 serum levels have been reported in several autoimmune diseases including MG patients from Japan.

Patients and methods

Sera of 42 seropositive MG patients (66.7% women), mean age 50.6±23.7 years) have been tested by ELISA for IL-15 levels.

Results

There were no statistically significant differences between IL-15 serum levels in MG patients in comparison with controls as well as between subgroups of MG patients (early vs. late onset and thymoma MG). Mean/median IL-15 serum levels were similar in MG patients treated with corticosteroids (CS) and CS naïve. Outliers (very high values) were seen only in untreated generalized MG patients.

Conclusions

Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity.

Get Citation

Keywords

Myasthenia gravis, Interleukin 15, Cytokine, Autoimmune disease

About this article
Title

Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 3 (2018)

Pages

364-367

DOI

10.1016/j.pjnns.2017.12.011

Bibliographic record

Neurol Neurochir Pol 2018;52(3):364-367.

Keywords

Myasthenia gravis
Interleukin 15
Cytokine
Autoimmune disease

Authors

Ewa Sobieszczuk
Justyna Kubiszewska
Marta Lipowska
Piotr Szczudlik
Beata Szyluk
Małgorzata Dutkiewicz
Anna Kostera-Pruszczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl